Deciphera Pharmaceuticals seeks to improve treatment for patients with cancer by designing kinase inhibitor therapies that target the hallmarks of cancer biology. We specifically design our small molecule compounds to simultaneously block multiple cancer signaling mechanisms in the tumor cell and the tumor microenvironment to prevent growth and spread. Deciphera's unique approach represents an important advance over current therapies in the durability of kinase inhibition and resiliency to genetic mutations to provide greater benefit across a range of cancers. Deciphera's business strategy is to advance its drug candidates for genetically defined cancers and cancers that target the tumor microenvironment through both proprietary and partnered programs.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/21/15 | $75,000,000 | Series B |
New Leaf Venture Partners | undisclosed |
| 01/05/16 | $90,000,000 | Series B |
New Leaf Venture Partners | undisclosed |
| 06/01/17 | $52,000,000 | Series C |
New Leaf Venture Partners Redmile Group  Sphera Global Healthcare Viking Global Investors | undisclosed |
